Impaired Vasoconstriction and Nitric Oxide-Mediated Relaxation in Pulmonary Arteries of Hypoxia- and Monocrotaline-Induced Pulmonary Hypertensive Rats

Virak Mam, Alain F. Tanbe, Sally H. Vitali, Elena Arons
Helen A. Christou, Raouf A. Khalil

Division of Vascular and Endovascular Surgery (VM, AFT, RAK),
and Division of Newborn Medicine (EA, HAC),
Brigham and Women’s Hospital,
and Department of Anesthesia, Children’s Hospital (SHV),
and Harvard Medical School, Boston, MA
Running Title: Vascular Function in Pulmonary Hypertension

Corresponding Author:
Raouf A Khalil, MD, PhD
Harvard Medical School
Brigham and Women's Hospital
Division of Vascular Surgery
75 Francis Street
Boston, MA 02115
Tel: (617) 525-8530
Fax: (617) 264-5124
E-mail: raouf_khalil@hms.harvard.edu

Document Statistics
Number of Text Pages 28
Number of Tables 1
Number of Figures 7
Number of References 40
Number of Words in Abstract 250
Number of Words in Introduction 425
Number of Words in Discussion 1498
List of Non-standard Abbreviations:

Ach  acetylcholine
EDRF  endothelium-derived relaxing factor
L-NAME  \(N^{\omega}\)-nitro-L-arginine methyl ester
LVSP  left ventricular systolic pressure
NO  nitric oxide
ODQ  1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one
PDE5  phosphodiesterase-5
PH  pulmonary hypertension
PHE  phenylephrine
RVSP  right ventricular systolic pressure
SNP  sodium nitroprusside
VSMC  vascular smooth muscle cell
ABSTRACT

Pulmonary hypertension (PH) is a life-threatening disease with unclear vascular mechanisms. We tested whether PH involves abnormal pulmonary vasoconstriction and impaired vasodilation. Male Sprague-Dawley rats were exposed to hypoxia (9% O₂) for 2-weeks or injected s.c. with single dose monocrotaline (MCT, 60mg/kg). Control rats were normoxic or injected with saline. After measuring the hemodynamics, pulmonary and mesenteric arteries were isolated for measurement of vascular function. Hematocrit was elevated in hypoxic rats. Right ventricular systolic pressure and Fulton's Index (right/(left+septum) ventricular weight) were greater in hypoxic and MCT-treated than normoxic rats. Pulmonary artery contraction to phenylephrine and 96mM KCl were less in hypoxic and MCT-treated than normoxic rats. Acetylcholine-induced relaxation was less in pulmonary artery of hypoxic and MCT-treated than normoxic rats, suggesting reduced effects of endothelium-derived vasodilators. The NOS inhibitor L-NAME and guanylate cyclase inhibitor ODQ inhibited acetylcholine relaxation, suggesting that it was mediated by NO-cGMP. The NO donor sodium nitroprusside caused less relaxation in pulmonary artery of hypoxic and MCT-treated than normoxic rats, suggesting decreased responsiveness of vascular smooth muscle cells (VSMCs) to vasodilators. Phenylephrine and KCl contraction, and acetylcholine and sodium nitroprusside relaxation were not different in mesenteric arteries from all groups. In lung tissue sections, the wall thickness of pulmonary arterioles was greater in hypoxic- and MCT-treated than normoxic rats. The specific reductions in pulmonary, but not systemic, arterial vasoconstriction and vasodilation in hypoxia- and MCT-induced PH are consistent with the possibility of de-differentiation of pulmonary VSMCs to a more proliferative/synthetic and less contractile phenotype in PH.
Introduction

Pulmonary Hypertension (PH) is a devastating disease characterized by increased pulmonary arterial blood pressure and right ventricular hypertrophy (Budhiraja et al., 2004; Farber & Loscalzo, 2004). Prognosis of PH is poor and early detection is critical (Runo & Loyd, 2003). The etiology of PH is not completely understood, but idiopathic and familial factors have been implicated. PH often occurs in children with congenital heart disease and after cardiac surgery (Hopkins et al., 1991), and also affects adults particularly with HIV infection, chronic obstructive pulmonary disease, and other cardiopulmonary disease (Fattouch et al., 2005). The course of PH progresses rapidly and ultimately leads to right ventricular failure and premature death (D’Alonzo et al., 1991). Understanding the vascular mechanisms involved in PH should help design specific and efficient therapy for this life-threatening disease.

Histological evidence has suggested that PH is associated with vascular remodeling of the small pulmonary arteries, vascular cell proliferation and obliteration of pulmonary microvasculature, leading to progressive increase in pulmonary vascular resistance and right ventricular failure (Pietra et al., 1989; Budhiraja et al., 2004; Farber & Loscalzo, 2004). Because vasodilators such as prostacyclin, nitrates and phosphodiesterase-5 inhibitors are commonly used as first line of treatment in severe PH (Burger, 2009; Stehlik & Movsesian, 2009; Yin et al., 2009), it is important to determine whether the responsiveness of the pulmonary circulation to vasodilators is affected in the setting of PH.

Previous studies have examined pulmonary vascular function in animal models of PH with variable results (Adnot et al., 1991; Barman, 2007, Fullerton et al., 1996; Gillespie et al., 1996; Shimoda et al., 2000). The variable results could be due to differences in the pulmonary hypertensive animal model, the experimental preparation (isolated perfused lung vs. vascular rings) or the vasoactive mediators used. Also, the specificity of the effects of PH on the
pulmonary circulation as compared to other systemic vascular beds has not been clearly established (Toporsian & Ward, 1997; Auer & Ward, 1998).

The present study was designed to test the hypothesis that PH involves alterations in the vasoconstriction and vasodilator responses that are specific to the pulmonary arteries. We measured the hemodynamics and examined the vascular function in two separate vascular beds, the pulmonary and mesenteric arteries, isolated from two different rat models of PH, the hypoxia and MCT-induced models, in order to determine: 1) Whether the responsiveness of the pulmonary arteries to vasoconstrictors is altered in PH, 2) Whether pulmonary arterial relaxation to endothelium-dependent NO-cGMP pathway is impaired in PH, and 3) Whether the pulmonary VSMC responsiveness to vasodilators is impaired in PH.

Methods

Animals and Exposures. Twelve-week-old (250 to 300 g) male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were housed in the animal facility in 12 hr/12 hr light/dark cycle, at 22±1°C ambient temperature and maintained on ad libitum normal Purina Rodent Chow (Purina, St. Louis, MO) and tap water. After 3 days of acclimatization, animals were exposed to hypoxia at 9% O₂ inside a chamber where O₂ is controlled to within a 0.2% range by an OxyCycler controller (BioSpherix, Redfield, NY) (Vitali et al., 2009). The controllers injected nitrogen and O₂ into the chamber to maintain the appropriate FiO₂, and ventilation was adjusted to remove CO₂ so that it does not exceed 5,000 ppm (0.5%). Ammonia was removed by ventilation and activated charcoal filtration using an electric air purifier. The duration of hypoxic exposure was 2 weeks. Normoxic rats breathed air under otherwise identical conditions. Age-matched rats were injected s.c. with a single dose of monocrotaline (MCT, 60 mg/kg/day) and examined 4 weeks later. Control rats were injected with saline. All experimental procedures followed the guidelines of, and were approved by, the
Harvard Institutional Animal Care and Use Committee.

**Right and Left Ventricular Systolic Pressure (RVSP and LVSP) Measurements.** Animals were anesthetized with 3% isoflurane inhalation and continued to breathe spontaneously. A small transverse incision was made in the abdominal wall, and the transparent diaphragm was exposed. A 23-gauge butterfly needle with tubing attached to a pressure transducer was inserted through the diaphragm first into the right ventricle and then into the left ventricle and pressure measurements were recorded with PowerLab monitoring hardware and software (ADInstruments, Colorado Springs, CO). Animals with heart rates less than 300 beats per minute were considered over-anesthetized and their RVSP and LVRP measurements were excluded. Mean RVSP and LVSP over the first 10 stable heartbeats were recorded.

**Hematocrit.** After hemodynamic measurements were completed, a 0.2 ml sample of blood was collected from the cardiac chambers for hematocrit determination in a blood gas analyzer.

**Tissue Preparation.** In euthanized rats, the thoracic cavity was opened, and the heart, lung and pulmonary arteries were rapidly excised. The abdominal cavity was then opened and the mesentery and mesenteric arterial arcade were excised and placed in oxygenated Krebs solution. The right and left pulmonary artery, and 2nd order mesenteric arteries were carefully dissected and cleaned of connective tissue under microscopic visualization, and cut into 3 mm-wide rings.

**Right Ventricular Weight Measurement and Determination of Fulton’s Index.** After the heart was excised, both ventricles were weighed, and then the right ventricular wall was dissected and the remaining left ventricular wall and ventricular septum were weighed. Fulton’s Index was calculated as the ratio of right ventricular weight/(left ventricular + septum weight).

**Isometric Contraction.** Vascular segments were suspended between two tungsten wire hooks,
one hook was fixed at the bottom of a tissue bath and the other hook was connected to a Grass force transducer (FT03, Astro-Med Inc., West Warwick, RI). Pulmonary artery and mesenteric artery segments from the same rat were stretched under 1 g or 0.5 g of resting tension, respectively (as determined by preliminary tension-contraction curves to KCl), and allowed to equilibrate for 45 min in a temperature controlled, water-jacketed tissue bath, filled with 50 ml Krebs solution continuously bubbled with 95% O₂ 5% CO₂ at 37°C. The changes in isometric contraction were recorded on a Grass polygraph (Model 7D, Astro-Med).

After tissue equilibration, a control contraction in response to 96 mM KCl was elicited. Once maximum KCl contraction was reached the tissue was rinsed with Krebs 3 times, 10 min each. The control KCl-induced contraction followed by rinsing in Krebs was repeated twice.

Vascular segments were stimulated with increasing concentrations of phenylephrine (PHE, 10⁻⁹ to 10⁻⁵ M), concentration-contraction curves were constructed, and the maximal PHE contraction was measured. The individual PHE concentration-response curves were further analyzed using a non-linear regression curve (best-fit sigmoidal dose-response curve, Sigmaplot), and the effective concentration that produced half the maximal contraction (ED₅₀) was measured and presented as pED₅₀ (-log M). In all experiments, the viability of the endothelium was verified by demonstrating acetylcholine (Ach)-induced relaxation in vascular segments precontracted with PHE. The tissues were precontracted with PHE (10⁻⁵ M), increasing concentrations (10⁻⁹ to 0⁻⁵ M) of Ach were added and the % relaxation of PHE contraction was measured. Parallel contraction and relaxation experiments were performed in endothelium-intact vascular rings pretreated with the NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME, 3x10⁻⁴ M) or the guanylate cyclase inhibitor 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10⁻⁵ M) for 10 min. In other experiments the relaxation to increasing concentrations (10⁻⁹ to 0⁻⁵ M) of the exogenous NO donor sodium nitroprusside (SNP) was measured in vascular rings precontracted with PHE.
Lung Histology and Morphometric Analysis. Lung sections (6 μm) were stained with hematoxylin and eosin and examined with light microscopy by two independent investigators (E.A. and H.A.C.) in a blinded fashion. Images of the arterioles were captured with a microscope digital camera and analyzed using an image analysis program (NIH Image). At least 15 arterioles of comparable size (50-100 μm diameter) per rat, from the lungs of 5 different rats from each experimental group were evaluated. The percent wall thickness was determined by dividing the area occupied by the vessel wall by the total cross sectional area of the arteriole as previously reported (Christou et al., 2000). This method accounts for uneven media thickness and areas that have obliquely sectioned pulmonary arterioles.

Solutions and Drugs. Krebs solution contained (in mM): NaCl 120, KCl 5.9, NaHCO₃ 25, NaH₂PO₄ 1.2, dextrose 11.5, CaCl₂ 2.5, MgCl₂ 1.2, at pH 7.4, and bubbled with 95% O₂ and 5% CO₂. 96 mM KCl was prepared as Krebs solution with equimolar substitution of NaCl with KCl. Stock solutions of PHE, Ach and L-NAME (10⁻¹ M, Sigma, St. Louis, MO) were prepared in distilled water. Stock solution of ODQ (10⁻¹ M) was prepared in DMSO. Final concentration of DMSO in experimental solution was <0.1%. All other chemicals were of reagent grade or better.

Statistical Analysis. The data were analyzed and presented as means±SEM. Vascular contraction and relaxation data were analyzed using Student’s ’t’-test for unpaired data. Concentration-contraction curves were further analyzed using non-linear regression best-fit sigmoidal curve (Sigmaplot). Histology and morphometric data were compared using a non-parametric Mann-Whitney test. Differences were considered statistically significant if P < 0.05.
RESULTS

Measurements of hemodynamics revealed signs of PH in hypoxic- and MCT-treated rats. Right ventricular systolic pressure, an indicator of the blood pressure in the pulmonary circulation, was significantly greater in hypoxic and MCT-treated than in normoxic rats (Table 1). In contrast, the left ventricular systolic pressure, an indicator of the blood pressure in the systemic circulation, was not significantly increased in the hypoxic rats, and was actually reduced in the MCT-treated rats compared to the control normoxic rats (Table 1).

Hematocrit, an indicator of hypoxia, was significantly greater in hypoxic than normoxic rats, and as expected, was not significantly different between MCT-treated and normoxic rats (Table 1). The Fulton's Index (right/(left+septum) ventricular weight) was significantly greater in hypoxic and MCT-treated rats (Table 1), indicating right ventricular hypertrophy compared to normoxic rats.

In pulmonary artery rings of normoxic rats, the $\alpha$-adrenergic agonist phenylephrine (PHE) caused concentration-dependent contraction that reached a maximum at $10^{-5}$M concentration (Fig. 1A). The PHE-induced contraction was significantly reduced in pulmonary artery rings from hypoxic and MCT-treated rats compared to normoxic rats (Fig. 1A, Table 1). When the PHE contraction was presented as % of max, and the ED50 was calculated, PHE appeared to be equally potent in the pulmonary arteries of the various groups of rats (Fig. 1C, Table 1). In contrast, in the mesenteric arteries, the PHE-induced maximum contraction did not appear to be different among the various groups of rats (Fig. 1B, Table 1). Also the PHE ED50 was not different in the mesenteric arteries of the different experimental groups (Fig. 1D, Table 1).

Pretreatment of pulmonary artery segments with the NOS inhibitor L-NAME ($3x10^{-4}$ M) for 10 min caused an increase in basal tension (0.29±0.12 g/mg tissue) and enhanced the magnitude of PHE contraction in normoxic rats (Fig. 2A, Table 1). Treatment of pulmonary artery with L-NAME caused a small increase in basal tension in hypoxic (0.15±0.07) and MCT-
treated rats (0.09±0.06 g/mg Tissue) and minimally enhanced the magnitude of PHE contraction (Fig. 2B, 2C, Table 1), and the PHE responses were still less than that in the control normoxic rats. Presenting the PHE contraction as % of max and measurement of PHE ED50 indicated that PHE was more potent in L-NAME-treated than nontreated normoxic rats (Fig. 2D, Table 1). The PHE contractile response as % of max was shifted to the left in L-NAME treated compared to nontreated pulmonary artery of hypoxic rats (Fig. 2E, Table 1). In contrast, the PHE contractile response as % of max and the PHE ED50 were not significantly different between L-NAME treated and nontreated pulmonary artery of MCT-treated rats (Fig. 2F, Table 1).

Pretreatment of pulmonary artery segments with the guanylate cyclase inhibitor ODQ (10⁻⁵ M) for 10 min caused an increase in basal tension (0.11±0.07 g/mg Tissue) and enhanced the magnitude of PHE contraction in normoxic rats (Fig. 2A, Table 1). ODQ caused an increase in basal tension in hypoxic (0.10±0.05) and MCT-treated rats (0.32±0.15 g/mg Tissue), and minimally enhanced PHE contraction, and the PHE responses were still less than that in the normoxic rats (Fig. 2B, 2C, Table 1). Presenting the PHE contraction as % of max and measurement of PHE ED50 indicated that PHE was equally potent in ODQ-treated than nontreated normoxic rats (Fig. 2D), but was more potent in ODQ treated than nontreated hypoxic and MCT-treated rats (Fig. 2E, 2F, Table 1).

Membrane depolarization by 96 mM KCl caused significant contraction in pulmonary artery of control normoxic rats. The KCl-induced contraction was significantly reduced in pulmonary arteries of hypoxic and MCT-treated rats (Fig. 3A). In contrast, KCl-induced contraction was not significantly different in mesenteric arteries of normoxic, hypoxic and MCT-treated rats (Fig. 3B).

Acetylcholine (Ach) caused concentration-dependent relaxation in PHE-precontracted pulmonary artery rings of normoxic rats that reached a maximum of 51.16±2.92% at 10⁻⁵ M
concentration. Ach-induced pulmonary artery relaxation was significantly reduced in hypoxic and MCT-treated rats compared to normoxic rats (Fig. 4A, Table 1), suggesting either reduced production of, or decreased responsiveness to, endothelium-derived vasodilators such as NO in the setting of experimental PH. In contrast, Ach relaxation was not significantly different in PHE-precontracted mesenteric artery rings of normoxic, hypoxic and MCT-treated rats (Fig. 4B, Table 1).

In pulmonary artery of normoxic rats, the NOS inhibitor L-NAME, and the guanylate cyclase inhibitor ODQ abolished Ach relaxation, suggesting the involvement of the NO-cGMP pathway (Fig. 5A). Pretreatment with L-NAME or ODQ also abolished the small Ach-induced relaxation in pulmonary artery of hypoxic and MCT rats (Fig. 5B, 5C), suggesting that the residual vasorelaxation response to Ach in experimental PH is mediated by the NO-cGMP pathway.

In pulmonary artery segments precontracted with PHE (10^{-5} M), the exogenous NO donor sodium nitroprusside (SNP) caused concentration-dependent relaxation that was significantly reduced in hypoxic and MCT-treated compared to normoxic rats (Fig. 6A, Table 1), suggesting decreased responsiveness of vascular smooth muscle cells (VSMCs) to vasodilators. In contrast, SNP-induced relaxation was not significantly different in mesenteric arteries of normoxic, hypoxic and MCT-treated rats (Fig. 6B, Table 1).

In order to correlate the vascular function observations in the pulmonary vessels to structural remodeling of the pulmonary arterioles, lung histology and morphometric analysis were performed on lung tissue sections from control normoxic rats, and hypoxic and MCT-treated rat models of PH. In lung tissue sections stained with hematoxylin and eosin, the % wall thickness of the pulmonary arterioles was significantly greater (p<0.001) in hypoxic- and MCT-treated PH rats as compared to control normoxic rats (Fig. 7). These data suggest significant pulmonary vascular remodeling in the hypoxic and MCT-treated rat models of PH.
DISCUSSION

An imbalance of the pulmonary vasoconstrictor and vasodilator stimuli has been implicated in the pathogenesis of PH (Ambalavanan et al., 2005; Fagan et al., 2004; Homma et al., 2007; Hoshikawa et al., 2001; Ivy et al., 2002; Schermuly 2005), and vasodilators aiming to restore the pulmonary vascular balance constitute the mainstay of current pharmacologic therapy (Burger, 2009; Stehlik & Movsesian, 2009; Yin et al., 2009). However, many patients fail to respond to vasodilators, possibly due to the ‘fixed’ component of PH caused by excessive pulmonary vascular remodeling. Understanding the mechanisms of pulmonary vascular remodeling would help design novel therapies to reverse the established pathology (Nozik-Grayck et al., 2007; Majka et al., 2008; Arciniegas et al., 2007). However, until those therapies are developed, a useful approach is to improve the responsiveness of the remodeled pulmonary circulation to vasodilators. We therefore sought to examine pulmonary vascular responsiveness to vasoactive stimuli in the hypoxic and MCT models of PH, which have significant pulmonary vascular remodeling (Christou et al., 2000; Schermuly et al., 2004).

The present study demonstrates that chronic hypoxia and MCT treatment in rats are associated with: 1) reduced pulmonary artery contraction to vasoconstrictor stimuli, 2) decreased endothelium-dependent NO-cGMP mediated pulmonary artery relaxation, and 3) decreased pulmonary artery responsiveness to nitrovasodilator. The hypoxia- and MCT-induced changes are specific to the pulmonary and not the mesenteric vessels.

We found that the pulmonary artery contraction to the α-adrenergic agonist PHE was reduced in hypoxic and MCT-treated rats. This is unlikely due to changes in the amount/sensitivity of α-adrenergic receptors because the PHE ED50 was not different between normoxic, hypoxic and MCT-treated rats. Also, membrane depolarization by high KCl, a receptor-independent response, was reduced in PH rats, suggesting a reduction in a common post-receptor contraction pathway in pulmonary VSMCs.
Previous studies have shown enhanced endothelin-1 (ET-1)-induced pulmonary vasoconstriction in the Fawn-Hooded rat model of spontaneous PH (Barman, 2007) and increased vasomotor tone in hypoxic PH (Shimoda et al., 2000; Oka et al., 2007). Chronic hypoxia is associated with increased ET-1 and angiotensin II (AngII) in the lung and changes in the receptor population, K⁺ current, membrane depolarization, cytosolic Ca²⁺ and Rho kinase in pulmonary VSMCs, leading to increased vascular contraction, pulmonary vascular resistance and PH (Shimoda et al., 2000; Oka et al., 2007). Our observed decrease in pulmonary artery contraction in hypoxic rats is different from these reports, but consistent with other reports that ET-1-induced pulmonary vasoconstriction was reduced in the hypoxic rat model of PH (Itoh et al., 1999). The different results could be related to the vasoconstrictive agonist or the vascular preparation used.

In the isolated perfused lung, Gillespie et al. (1986) demonstrated that pulmonary vascular responsiveness to AngII, but not high KCl, was augmented in MCT-treated rats at day-4 and -7, but not day-14. Our findings of decreased PHE-induced pulmonary artery contraction on day 28 post-MCT treatment are consistent with this report, and suggest that while some enhanced responsiveness may occur prior to development of PH, this early alteration may not contribute to the sustained elevation in pulmonary arterial pressure.

We examined whether the impaired pulmonary vasoconstriction in experimental PH is due to enhanced release of endothelium-derived relaxing factors such as nitric oxide (NO). Blockade of NO production by L-NAME enhanced PHE potency in hypoxic and to a lesser extent in MCT-treated rats. Also, inhibition of guanylate cyclase and cGMP production by ODQ enhanced PHE potency in hypoxic and MCT-treated rats, suggesting potential increase in the NO-cGMP vasodilator pathway as a compensatory mechanism to PH. However, even with NOS or guanylate cyclase inhibition, PHE contraction remained less in hypoxic and MCT-treated than normoxic rats, suggesting that the α-adrenergic post-receptor signaling
mechanisms or the pulmonary artery contractile machinery are not responsive to PHE. Also, the reduced Ach-induced relaxation in pulmonary arteries of hypoxic and MCT-treated rats is unlikely due to decreased endothelial cholinergic receptors or NO synthase because the pulmonary artery relaxation to the NO donor SNP was also reduced in PH rats. Although the reduced Ach relaxation in the PH rats could be due to increased oxidative stress and decreased NO bioavailability in hypoxic rats (Cowan et al., 2003), it cannot account for the reduced Ach relaxation in the MCT rats. Also, the enhanced PHE contraction in L-NAME or ODQ treated pulmonary arteries of hypoxic rats suggests that NO production/bioavailability was not significantly compromised. A more plausible explanation for the reduced Ach relaxation in PH rats is the development of structural changes in the pulmonary vascular wall that decrease the responsiveness of pulmonary VSMCs to vasodilators. This is supported by the reduced pulmonary artery relaxation to the NO donor SNP in PH rats. However, the decreased responsiveness to SNP could also be due to increased phosphodiesterase-5 (PDE5) or decreased protein kinase G activity.

Studies in isolated perfused lung suggested reduced synthesis/responsiveness to EDRF in hypoxic models of PH. Adnot et al. (1991) demonstrated that Ach-induced relaxation was reduced in rats exposed to 1-wk hypoxia and abolished after 3-wk hypoxia. They also found enhanced pressor response to ET-1, no potentiation of the pressor response by the EDRF antagonists hydroquinone and methylene blue, and fully active endothelium-independent vasodilation by SNP in hypoxic rats, and concluded that hypoxia-induced PH is associated with a loss of EDRF activity in pulmonary vessels. We observed potentiation of PHE contraction in pulmonary arteries of hypoxic rats by L-NAME or ODQ, suggesting that the NO-cGMP activity is preserved. Also, SNP-induced relaxation was reduced in pulmonary arteries of hypoxic rats. The different results could be related to the vascular preparation (pulmonary artery vs. isolated perfused lung), or the NO-cGMP blocker used (L-NAME and ODQ vs.
hydroquinone and methylene blue). The reduced Ach- and SNP-induced relaxation in pulmonary arteries of MCT-treated rats is consistent with the report that both endothelium-dependent and -independent relaxation are reduced in the rat model of MCT-induced progressive lung injury (Fullerton et al., 1996).

The cause of the decreased contraction to PHE and KCl, and the impaired Ach and SNP relaxation in the pulmonary artery of PH rats is unclear, but could be related to extensive vascular remodeling and pulmonary VSMC growth and proliferation. This is supported by reports that PH is associated with remodeling of the small pulmonary arteries, vascular cell proliferation and obliteration of the pulmonary microvasculature (Budhiraja et al., 2004; Farber & Loscalzo, 2004, Mitani et al., 2001; Pietra et al., 1989). Also, hypoxia is associated with increased proliferation and migration of VSMCs, and a synthetic pulmonary VSMC phenotype (Cooper & Beasley, 1999; Chen et al., 2008; Schultz et al., 2006). The observed increase in wall thickness in pulmonary arterioles of PH rats supports the contention that the decreased pulmonary artery responsiveness to both vasoconstrictor and vasodilator stimuli is related to pulmonary vascular remodeling and potential change in pulmonary VSMCs from a contractile to proliferative phenotype.

Hypoxia has diverse effects on the pulmonary and systemic vascular tone. Acute hypoxia elicits vascular adaptations that redistribute blood flow to metabolically active tissues and improve the capacity for O2 extraction (Doyle & Walker, 1991; Kuwahira et al., 1993). On the other hand, hypoxia for 16 to 48 hours may cause reduction in contraction of systemic arteries in response to agonist stimulation or transmural pressure. Large vessels such as the aorta as well as skeletal muscle, diaphragmatic and mesenteric arterioles could be affected (Auer & Ward, 1998; Doyle & Walker, 1991; Kuwahira et al., 1993; Toporsian & Ward, 1997). Although MCT treatment may cause both pulmonary and systemic vascular inflammation and endothelial damage, MCT-treated rats have been used as a model of progressive lung injury.
and PH (Gillespie et al., 1986; Fullerton et al., 1996). In our hypoxia and MCT models of PH, we found no changes in the responsiveness of the mesenteric vessels to vasoconstrictor or vasodilator stimuli, indicating specific changes in the pulmonary but not the systemic circulation in experimental PH.

The observed results in extra-lobar first branch pulmonary arteries may not reflect the entire pulmonary circulation. Future studies should examine whether the reduced contraction/relaxation in extra-lobar pulmonary arteries also occur in the intralobar resistance, which play a major role in the increased vascular resistance associated with PH. However, given that there is increasing appreciation of the contribution of proximal vascular stiffness to pulmonary vascular impedance in the setting of PH (Lammers et al., 2008, Sanz et al., 2009), it is equally important to examine these responses in experimental PH.

Our results may have important experimental and clinical implications for PH. The results raise the possibility that unless approaches to improve responsiveness of the pulmonary circulation to vasoactive substances are developed, therapeutic interventions targeting vasoconstriction may not produce the desired effects.

In conclusion, hypoxia- and MCT-induced PH is associated with reduced responsiveness of the pulmonary arterial circulation to both vasoconstrictor and vasodilator stimuli. The specific reduction in the pulmonary vascular responses in the setting of hypoxia and MCT-induced PH may be explained by a vascular bed-specific switch of VSMCs from the contractile to the synthetic phenotype, and this needs to be further examined in future studies.

ACKNOWLEDGEMENTS

We acknowledge the generous support of Drs. S. Kourembanas and S.A. Mitsialis in the development of the hypoxic rat model.
REFERENCES


Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, and


FOOTNOTES

R. A. Khalil was partly supported by grants from the National Heart, Lung, and Blood Institute [HL-65998 and HL-70659], and The Eunice Kennedy Shriver National Institute of Child Health and Human Development [HD-60702].
LEGENDS FOR FIGURES

Fig. 1. PHE-induced contraction in pulmonary and mesenteric artery segments of normoxic, hypoxic and MCT-treated rats. Pulmonary artery (A and C) and mesenteric artery rings (B and D) were stimulated with increasing concentrations of PHE. The contractile response was measured and presented in g/mg tissue weight for pulmonary vessels (A) or in g for mesenteric vessels (B) or as % of maximum PHE contraction (C and D). Data represent means±SEM (n=6 to 16).

* Measurements in hypoxic and MCT-treated rats are significantly different (p<0.05) from corresponding measurements in normoxia rats.

Fig. 2. Effect of blockade of the NO-cGMP pathway on PHE-induced contraction in pulmonary artery segments of normoxic, hypoxic and MCT-treated rats. Pulmonary artery segments of normoxic (A and D), hypoxic (B and E) and MCT-treated rats (C and F) were either nontreated (open circle) or pretreated with the NOS inhibitor L-NAME (3x10^{-4} M) (closed circles), or the guanylate cyclase inhibitor ODQ (10^{-5} M) (open triangles) for 10 min. The tissues were stimulated with increasing concentrations of PHE, and the contractile response was measured and presented as g/mg tissue weight (A, B and C) or as % of maximum PHE contraction (D, E and F). Data represent means±SEM (n=6 to 16).

* Measurements in L-NAME or ODQ-treated pulmonary artery segments are significantly different (p<0.05) from corresponding measurements in non-treated segments.

Fig. 3. KCl-induced contraction in pulmonary and mesenteric artery segments of normoxic, hypoxic and MCT-treated rats. Pulmonary artery (A) and mesenteric artery segments (B) were stimulated with KCl (96 mM) and the contractile response was presented in g/mg tissue weight for pulmonary vessels (A) or in g for mesenteric vessels (B). Data represent means±SEM (n=6
to 16).

* Measurements in hypoxic and MCT-treated rats are significantly different (p<0.05) from corresponding measurements in normoxic rats.

Fig. 4. Ach-induced relaxation in pulmonary and mesenteric artery segments of normoxic, hypoxic and MCT-treated rats. Pulmonary artery (A) and mesenteric artery segments (B) were precontracted with PHE (10^{-5} M), increasing concentrations of Ach were added and the % relaxation of PHE contraction was measured. Data represent means±SEM (n=6 to 16).

* Measurements in hypoxic and MCT-treated rats are significantly different (p<0.05) from corresponding measurements in normoxic rats.

Fig. 5. Effect of blockade of the NO-cGMP pathway on Ach-induced relaxation in pulmonary artery segments of normoxic, hypoxic and MCT-treated rats. Pulmonary artery segments of normoxic (A), hypoxic (B) and MCT-treated rats (C) were either nontreated (open circle) or pretreated with the NOS inhibitor L-NAME (3x10^{-4} M) (closed circles), or the guanylate cyclase inhibitor ODQ (10^{-5} M) (open triangles) for 10 min. The tissues were precontracted with PHE (10^{-5} M), increasing concentrations of Ach were added and the % relaxation of PHE contraction was measured. Data represent means±SEM (n=6 to 16).

* Measurements in L-NAME or ODQ-treated pulmonary artery segments are significantly different (p<0.05) from corresponding measurements in non-treated segments.
Fig. 6. SNP-induced relaxation in pulmonary and mesenteric artery segments of normoxic, hypoxic and MCT-treated rats. Pulmonary artery (A) and mesenteric artery segments (B) were contracted with PHE (10^{-5} M), increasing concentrations of SNP were added and the % relaxation of PHE contraction was measured. Data represent means±SEM (n=3 to 8).

* Measurements in hypoxic and MCT-treated rats are significantly different (p<0.05) from corresponding measurements in normoxic rats.

Fig. 7. Pulmonary vascular remodeling in hypoxic and MCT-treated models of PH. A) Representative H&E of peripheral lung sections from control normoxic rat, and hypoxic (2 weeks) and MCT-treated rats. Pulmonary arterioles are indicated with arrows. Total magnification X400. Scale bar = 50 μm. B) Quantitative morphometric analysis of % wall thickness of pulmonary arterioles defined as the area occupied by the vessel wall divided by the total cross sectional area of the arteriole. Graph bars represent the means±SEM of measurements in 15 vessels per rat, 5 rats from each experimental group. * p<0.001 compared to the normoxic group.
Table 1. Hemodynamics, Hematocrit, Fulton’s Index, PHE Contraction, and Ach and SNP relaxation in pulmonary and mesenteric arteries of normoxic, hypoxic and MCT-treated rats.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Hypoxia</th>
<th>MCT-Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right Ventricular Systolic Pressure (RVSP) (mmHg)</td>
<td>26.3±4.9 (4)</td>
<td>60.2±2.1 (10) *</td>
<td>56.2±6.8 (5) *</td>
</tr>
<tr>
<td>Left Ventricular Systolic Pressure (LVSP) (mmHg)</td>
<td>117.5±4.3 (3)</td>
<td>124.6±5.7 (6)</td>
<td>98.2±4.7 (5) *</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>38.5±1.2 (14)</td>
<td>63.3±2.3 (8) *</td>
<td>41±1 (7)</td>
</tr>
<tr>
<td>Fulton’s Index</td>
<td>0.28±0.01 (17)</td>
<td>0.57±0.02 (12) *</td>
<td>0.51±0.03 (8) *</td>
</tr>
</tbody>
</table>

**Pulmonary Artery**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Hypoxia</th>
<th>MCT-Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max (10^{-5} M) Contraction (g/mg)</td>
<td>1.03±0.11 (16)</td>
<td>0.28±0.05 (12) *</td>
<td>0.56±0.15 (12) *</td>
</tr>
<tr>
<td>+ L-NAME (3x10^{-4} M)</td>
<td>1.15±0.15 (8)</td>
<td>0.36±0.11 (6) *</td>
<td>0.65±0.26 (6)</td>
</tr>
<tr>
<td>+ ODQ (10^{-5} M)</td>
<td>1.45±0.27 (8)</td>
<td>0.38±0.11 (6) *</td>
<td>0.81±0.24 (6)</td>
</tr>
<tr>
<td>pED_{50} (-log M)</td>
<td>7.64±0.13 (16)</td>
<td>7.57±0.08 (12)</td>
<td>7.43±0.07 (12)</td>
</tr>
<tr>
<td>+ L-NAME (3x10^{-4} M)</td>
<td>7.93±0.07 (8)</td>
<td>7.71±0.24 (6)</td>
<td>7.53±0.15 (6) *</td>
</tr>
<tr>
<td>+ ODQ (10^{-5} M)</td>
<td>7.86±0.11 (8)</td>
<td>7.94±0.17 (6) #</td>
<td>8.07±0.06 (6) #</td>
</tr>
<tr>
<td>Ach (10^{-5} M) % Relaxation</td>
<td>51.2±2.9 (16)</td>
<td>19.5±5.4% (12) *</td>
<td>9.3±2.8% (12) *</td>
</tr>
<tr>
<td>SNP (10^{-5} M) % Relaxation</td>
<td>95.2±2.1 (8)</td>
<td>78.2±7.7 (6) *</td>
<td>50.4±5.5 (8) *</td>
</tr>
</tbody>
</table>

**Mesenteric Artery**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Hypoxia</th>
<th>MCT-Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max (10^{-5} M) Contraction (g)</td>
<td>0.89±0.09 (8)</td>
<td>0.70±0.12 (6)</td>
<td>0.76±0.11 (6)</td>
</tr>
<tr>
<td>pED_{50} (-log M)</td>
<td>6.29±0.15 (8)</td>
<td>6.36±0.16 (6)</td>
<td>6.42±0.20 (6)</td>
</tr>
<tr>
<td>Ach (10^{-5} M) % Relaxation</td>
<td>100.0±0.0 (8)</td>
<td>97.3±1.8 (6)</td>
<td>97.9±1.1 (6)</td>
</tr>
<tr>
<td>SNP (10^{-5} M) % Relaxation</td>
<td>100.0±0.0 (3)</td>
<td>100.0±0.0 (3)</td>
<td>100.0±0.0 (4)</td>
</tr>
</tbody>
</table>

Data represent means±SEM (n).

* Measurements in hypoxia or MCT-treated rats are significantly different (p<0.05) from corresponding measurements in normoxic rats.

# Measurements in L-NAME or ODQ-treated arteries are significantly different from corresponding measurement in non-treated arteries.
Figure 1
Figure 2
Figure 3

**A. Pulmonary Artery**

- **KCl Contraction (g/mg)**
  - Control: 1.2 ± 0.05
  - Hypoxia: 0.4 ± 0.03
  - MCT: 1.0 ± 0.03

**B. Mesenteric Artery**

- **KCl Contraction (g)**
  - Control: 1.0 ± 0.03
  - Hypoxia: 0.8 ± 0.02
  - MCT: 1.0 ± 0.03

Note: * indicates statistical significance compared to control.
Figure 4

A  Pulmonary Artery

B  Mesenteric Artery

% Relaxation vs. log [ACh] (M)

Legend:
- ○ Control
- ▲ Hypoxia
- ▲ MCT

**
Figure 5
Figure 6

A. Pulmonary Artery

B. Mesenteric Artery

% Relaxation vs. log [SNP] (M) for control, hypoxia, and MCT treatments in both pulmonary and mesenteric arteries.
Figure 7